What is Zika Virus?
Overview
Zika virus is a mosquito-borne virus first identified in Uganda in 1947 in a Rhesus macaque monkey followed by evidence of infection and disease in humans in other African countries in the 1950s.
From the 1960s to 1980s, sporadic human infections were detected across Africa and Asia. However, since 2007 outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific.
In outbreaks over the last decade Zika virus infection was found to be associated with increased incidence of Guillain-Barré syndrome. When Zika virus emerged in the Americas, with a large epidemic in Brazil in 2015, an association between Zika virus infection and microcephaly (smaller than normal head size) was first described; there were similar findings in French Polynesia upon retrospective review. From February to November 2016, WHO declared a Public Health Emergency of International Concern (PHEIC) regarding microcephaly, other neurological disorders and Zika virus, and the causal link between Zika virus and congenital malformations was soon confirmed (1,2). Outbreaks of Zika virus disease were identified throughout most of the Americas and in other regions with established Aedes aegypti mosquitos. Infections were detected in travellers from active transmission areas and sexual transmission was confirmed as an alternate route of Zika virus infection.
Cases of Zika virus disease globally declined from 2017 onwards; however, Zika virus transmission persists at low levels in several countries in the Americas and in other endemic regions. In addition, the first local mosquito-transmitted Zika virus disease cases were reported in Europe in 2019 and Zika virus outbreak activity was detected in India in 2021. To date, a total of 89 countries and territories have reported evidence of mosquito transmitted Zika virus infection; however, surveillance remains limited globally.
Symptoms
Most people infected with Zika virus do not develop symptoms. Among those who do, they typically start 3–14 days after infection, are generally mild including rash, fever, conjunctivitis, muscle and joint pain, malaise and headache, and usually last for 2–7 days. These symptoms are common to other arboviral and non-arboviral diseases; thus, the diagnosis of Zika virus infection requires laboratory confirmation.
Complications
Zika virus infection during pregnancy is a cause of microcephaly and other congenital malformations in the infant, including limb contractures, high muscle tone, eye abnormalities and hearing loss. These clinical features are collectively referred to as congenital Zika syndrome.
The risk of congenital malformations following infection in pregnancy remains unknown; an estimated 5–15% of infants born to women infected with Zika virus during pregnancy have evidence of Zika-related complications (3). Congenital malformations occur following both symptomatic and asymptomatic infection. Zika infection in pregnancy can also cause complications such as fetal loss, stillbirth and preterm birth.
Zika virus infection can also cause Guillain-Barré syndrome, neuropathy and myelitis, particularly in adults and older children.
Research is ongoing to investigate the risk and effects of Zika virus infection on pregnancy outcomes, strategies for prevention and control, and effects of infection on other neurological disorders in children and adults.
Transmission
Zika virus is primarily transmitted by infected mosquitoes of the Aedes (Stegomyia) genus, mainly Aedes aegypti, in tropical and subtropical regions. Aedes mosquitoes usually bite during the day. These mosquitoes also transmit dengue, chikungunya and urban yellow fever.
Zika virus is also transmitted from mother to fetus during pregnancy, as well as through sexual contact, transfusion of blood and blood products, and possibly through organ transplantation.
Diagnosis
Infection with Zika virus may be suspected based on symptoms of persons living in or visiting areas with Zika virus transmission and/or Aedes mosquito vectors. A diagnosis of Zika virus infection can only be confirmed by laboratory tests of blood or other body fluids, and it must be differentiated from cross-reactive flaviviruses such as dengue virus, to which the patient may have been exposed or previously vaccinated.
Treatment
There is no specific treatment available for Zika virus infection or disease.
People with symptoms such as rash, fever or joint pain should get plenty of rest, drink fluids, and treat symptoms with antipyretics and/or analgesics. Nonsteroidal anti-inflammatory drugs should be avoided until dengue virus infections are ruled out because of bleeding risk. If symptoms worsen, patients should seek medical care and advice.
Pregnant women living in areas with Zika transmission or who develop symptoms of Zika virus infection should seek medical attention for laboratory testing, information, counselling and other clinical care.
Prevention
No vaccine is yet available for the prevention or treatment of Zika virus infection. Development of a Zika vaccine remains an active area of research